On August 13, 2019, Elanco Animal Health Inc., (Indiana USA, Elanco), announced
that GALLIPRANT®, an EP4 receptor antagonist, was approved in Brazil for the
treatment of pain associated with osteoarthritis in dogs.
For details, please refer the announce by Elanco.

https://www.elanco.com/news/press-releases/elanco-q2-earnings